Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma-Reference-Cited by-同舟云学术

Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

Published:2014-05-15 Issue:20 Volume:123 Page:3128-3138
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tai Yu-Tzu¹,Mayes Patrick A.²,Acharya Chirag¹,Zhong Mike Y.¹,Cea Michele¹,Cagnetta Antonia¹,Craigen Jenny³,Yates John³,Gliddon Louise³,Fieles William⁴,Hoang Bao⁴,Tunstead James⁴,Christie Amanda L.⁵,Kung Andrew L.⁶,Richardson Paul¹,Munshi Nikhil C.¹,Anderson Kenneth C.¹

Affiliation:

1. The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

2. Oncology Research & Development, GlaxoSmithKline, Collegeville, PA;

3. Biopharm Discovery, GlaxoSmithKline, Stevenage, United Kingdom;

4. Platform Technology & Science Research & Development, GlaxoSmithKline, Collegeville, PA;

5. Lurie Family Imaging Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and

6. Department of Pediatrics, Columbia University Medical Center, New York, NY

Abstract

Key Points Selective myeloma cell killing and enhanced effector function of a novel anti-BCMA antibody conjugated with MMAF via noncleavable linker. Specific multiple myeloma antigen for monoclonal antibody-based immunotherapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/20/3128/1376404/3128.pdf

Reference44 articles.

1. Antibody-based therapies in multiple myeloma.;Tai,2011

2. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.;Jakubowiak;J Clin Oncol,2012

3. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.;Hsi;Clin Cancer Res,2008

4. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.;Tai;Blood,2008

5. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.;Lonial;J Clin Oncol,2012

Cited by 350 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma;Cell Death Discovery;2024-01-27

2. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors;Journal of Hematology & Oncology;2024-01-04

3. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial;Nature Medicine;2024-01-04

4. Slit-lamp findings in a case of belantamab-induced microcystic hurricane keratopathy;Journal Français d'Ophtalmologie;2024-01

5. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors;Critical Reviews in Oncology/Hematology;2024-01